Loading...

ERNA ERNEXA THERAPEUTICS INC Capital Structure Changes 8-K Filing

RNX

RN

ERNEXA THERAPEUTICS INC

(ERNA)

2023 8-K

Show Summary

Summary

Equity Offerings

Increase in authorized shares

Securities Agreement

Promissory Note Issued

Promissory Note Issued

Annual Meeting Notice

Nasdaq Compliance Notice

Nasdaq Compliance Notice

Private Placement

New License Agreement

Nasdaq Compliance Issue

Annual Meeting Notice

Delisting Notice

Appointment of Director

Private Placement of Conver...

Promissory Note Issued

License Agreement

Appointment of Dr. James Br...

Appointment of Director

Investor Presentation

Equity Offerings

Annual Meeting Voting Results

Appointment and Resignation

Asset Purchase Agreement

Financial Results Announcement

Exclusive License Agreement...

Resignation of CMO

Delisting and Management Ap...

External Links:

Eterna Therapeutics Inc. received a notice from Nasdaq stating that its stockholders' equity fails to comply with the minimum requirement for continued listing, and the company applied to transfer its listing to The Nasdaq Capital Market. The company also appointed Dr. Matthew Angel as President and CEO.

AI Assistant

ERNEXA THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.